Introduction: Cervical cancer is primarily caused by the human papilloma virus (HPV), which transforms normal cervical cells into cancerous cells that are highly resistant to radiation and chemotherapy. Induction of apoptosis in transformed cells is a key strategy in successfully treating HPV-induced cervical cancer. TRAIL (tumor necrosis factor related apoptosis-inducing ligand) has been shown to selectively induce apoptosis in cancer cells by binding to death receptors and activating extrinsic pathways for apoptosis. However, certain cervical cancers—such as the cultured cell line SiHa—are remarkably resistant to TRAIL. In this study, SiHa cells were sensitized to TRAIL by using sanguinarine—derived from the plant Sanguinaria Canadensis —which is known to induce oxidative stress and lead to the upregulation of receptors for TRAIL. Methods: Cultured SiHa cells were exposed to sub-lethal doses of sanguinarine in combination with TRAIL. Cell viability changes as well as the production of reactive oxygen species (ROS) were assessed. The induction of apoptosis was investigated by assays for caspase activation. Flow cytometry was performed to analyze expression of death receptors 4/5. Results: Treatment of SiHa cells with a combination of sanguinarine and TRAIL led to a significant reduction in cell viability. Significant increase in ROS was observed and caspase activation assays confirmed the induction of apoptosis. Conclusions: The observed synergistic effect of sanguinarine and TRAIL on SiHa cells is promising for the treatment of cervical, and possibly other, HPV-induced cancers. Oxidative stress caused by sanguinarine seems to play a central role in this synergy. The precise link between reactive oxygen species and the possible upregulation of death receptors needs further investigation. This knowledge will enable us to devise more effective treatments for those who suffer from this devastating disease.
KeywordsCervical Cancer SiHa CellsHuman Papilloma Virus (HPV)SanguinarineTRAIL (Tumor Necrosis Factor Related Apoptosis-Inducing Ligand)
American Cancer Society. (2015) Global Cancer Facts & Figures. 3rd Edition, American Cancer Society, Atlanta.
Siegel, R.L., Miller, K.D., and Jemal, A. (2015) Cancer Statistics, 2015. CA: A Cancer Journal for Clinicians, 65, 5-29. https://doi.org/10.3322/caac.21254
Fitzmaurice, C., Dicker, D., Pain, A., et al. (2015) The Global Burden of Cancer 2013. JAMA Oncology, 1, 505-527. https://doi.org/10.1001/jamaoncol.2015.0735
Walboomers, J.M., Jacobs, M.V., Manos, M.M., et al. (1999) Human Papillomavirus Is a Necessary Cause of Invasive Cervical Cancer Worldwide. The Journal of Pathology, 189, 12-19. https://doi.org/10.1002/(sici)1096-9896(199909)189:1 3.0.co;2-f
Ghittoni, R., Accardi, R., Chiocca, S., et al. (2015) Role of Human Papillomaviruses in Carcinogenesis. Ecancer Medical Science, 9, 526. https://doi.org/10.3332/ecancer.2015.526
Bell, M.C. and Alvarez, R.D. (2005) Chemoprevention and Vaccines: A Review of the Nonsurgical Options for the Treatment of Cervical Dysplasia. International Journal of Gynecological Cancer, 15, 4-12. https://doi.org/10.1111/j.1048-891X.2005.15002.x
Govan, V.A. (2008) A Novel Vaccine for Cervical Cancer: Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) Recombinant Vaccine (Gardasil). Therapeutics and Clinical Risk Management, 4, 65-70. https://doi.org/10.2147/TCRM.S856
Vale, C.L. (2010) Reducing Uncertainties about the Effects of Chemoradiotherapy for Cervical Cancer: Individual Patient Data Meta-Analysis. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008285/abstract
Kim, Y.S., Shin, S.S., Nam, J.H., et al. (2008) Prospective Randomized Comparison of Monthly Fluorouracil and Cisplatin Versus Weekly Cisplatin Concurrent with Pelvic Radiotherapy and High-Dose Rate Brachytherapy for Locally Advanced Cervical Cancer. Gynecologic Oncology, 108, 195-200. https://doi.org/10.1016/j.ygyno.2007.09.022
Ang, K.K. (2005) Concurrent Radiation Chemotherapy for Locally Advanced Head and Neck Carcinoma: Are We Addressing Burning Subjects? Journal of Clinical Oncology, 23, 248.
Lapresa, M., Parma, G., Portuesi, R., et al. (2015) Neoadjuvant Chemotherapy in Cervical Cancer: An Update. Expert Review of Anticancer Therapy, 15, 1171-1181. https://doi.org/10.1586/14737140.2015.1079777
Eaton, S., Wiktor, P., Thirstrup, D., et al. (2011) Efficacy of Trail Treatment against Hpv16 Infected Cervical Cancer Cells Undergoing Senescence Following Sirna Knockdown of E6/E7 Genes. Biochemical and Biophysical Research Communications, 405, 1-6. https://doi.org/10.1016/j.bbrc.2010.12.056
Hao, Z., Han, X., Sun, X., et al. (2016) Fully Human Monoclonal Antibodies to Trail-R1 Enhance Trail-Induced Apoptosis via Activation of Caspase-8 Pathway. Biochemical and Biophysical Research Communications, 475, 238-244. https://doi.org/10.1016/j.bbrc.2016.05.089
Kiraz, Y., Adan, A., Kartal Yandim, M., et al. (2016) Major Apoptotic Mechanisms and Genes Involved in Apoptosis. Tumor Biology, 37, 8471-8486. https://doi.org/10.1007/s13277-016-5035-9
Reesink-Peters, N., Hougardy, B.M., van den Heuvel, F.A., et al. (2005) Death Receptors and Ligands in Cervical Carcinogenesis: An Immunohistochemical Study. Gynecologic Oncology, 96, 705-713. https://doi.org/10.1016/j.ygyno.2004.10.046
de Miguel, D., Lemke, J., Anel, A., et al. (2016) Onto Better Trails for Cancer Treatment. Cell Death and Differentiation, 23, 733-747. https://doi.org/10.1038/cdd.2015.174
Hougardy, B.M., Maduro, J.H., van der Zee, A.G., et al. (2006) Proteasome Inhibitor Mg132 Sensitizes Hpv-Positive Human Cervical Cancer Cells to Rhtrail-Induced Apoptosis. International Journal of Cancer, 118, 1892-1900. https://doi.org/10.1002/ijc.21580
Lemke, J., von Karstedt, S., Zinngrebe, J., et al. (2014) Getting Trail Back on Track for Cancer Therapy. Cell Death and Differentiation, 21, 1350-1364. https://doi.org/10.1038/cdd.2014.81
Micheau, O., Shirley, S. and Dufour, F. (2013) Death Receptors as Targets in Cancer. British Journal of Pharmacology, 169, 1723-1744. https://doi.org/10.1111/bph.12238
Herbst, R.S., Eckhardt, S.G., Kurzrock, R., et al. (2010) Phase I Dose-Escalation Study of Recombinant Human Apo2l/Trail, a Dual Proapoptotic Receptor Agonist, in Patients with Advanced Cancer. Journal of Clinical Oncology, 28, 2839-2846. https://doi.org/10.1200/JCO.2009.25.1991
Soria, J.C., Smit, E., Khayat, D., et al. (2010) Phase 1b Study of Dulanermin (Recombinant Human Apo2l/Trail) in Combination with Paclitaxel, Carboplatin, and Bevacizumab in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 28, 1527-1533. https://doi.org/10.1200/JCO.2009.25.4847
Choi, W.Y., Jin, C.Y., Han, M.H., et al. (2009) Sanguinarine Sensitizes Human Gastric Adenocarcinoma Ags Cells to Trail-Mediated Apoptosis via Down-Regulation of Akt and Activation of Caspase-3. Anticancer Research, 29, 4457-4465. http://ar.iiarjournals.org/content/29/11/4457.long
Kim, S., Lee, T.J., Leem, J., et al. (2008) Sanguinarine-Induced Apoptosis: Generation of Ros, Down-Regulation of Bcl-2, C-Flip, and Synergy with Trail. Journal of Cellular Biochemistry, 104, 895-907. https://doi.org/10.1002/jcb.21672
Hussain, A.R., Al-Jomah, N.A., Siraj, A.K., et al. (2007) Sanguinarine-Dependent Induction of Apoptosis in Primary Effusion Lymphoma Cells. Cancer Research, 67, 3888-3897. https://doi.org/10.1158/0008-5472.CAN-06-3764
Ahmad, N., Gupta, S., Husain, M.M., et al. (2000) Differential Antiproliferative and Apoptotic Response of Sanguinarine for Cancer Cells Versus Normal Cells. Clinical Cancer Research, 6, 1524-1528. http://clincancerres.aacrjournals.org/content/6/4/1524.long
Xu, J.Y., Meng, Q.H., Chong, Y., et al. (2012) Sanguinarine Inhibits Growth of Human Cervical Cancer Cells through the Induction of Apoptosis. Oncology Reports, 28, 2264-2270.
Lum, J.J., Pilon, A.A., Sanchez-Dardon, J., et al. (2001) Induction of Cell Death in Human Immunodeficiency Virus-Infected Macrophages and Resting Memory Cd4 T Cells by Trail/Apo2l. Journal of Virology, 75, 11128-11136. https://doi.org/10.1128/JVI.75.22.11128-11136.2001
Shivapurkar, N., Toyooka, S., Toyooka, K.O., et al. (2004) Aberrant Methylation of Trail Decoy Receptor Genes Is Frequent in Multiple Tumor Types. International Journal of Cancer, 109, 786-792. https://doi.org/10.1002/ijc.20041
Spierings, D.C., de Vries, E.G., Vellenga, E., et al. (2004) Tissue Distribution of the Death Ligand Trail and Its Receptors. Journal of Histochemistry and Cytochemistry, 52, 821-831. https://doi.org/10.1369/jhc.3A6112.2004
Nimmanapalli, R., Perkins, C.L., Orlando, M., et al. (2001) Pretreatment with Paclitaxel Enhances Apo-2 Ligand/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis of Prostate Cancer Cells by Inducing Death Receptors 4 and 5 Protein Levels. Cancer Research, 61, 759-763. http://cancerres.aacrjournals.org/content/61/2/759.long
Wang, D., Upadhyaya, B., Liu, Y., et al. (2014) Phenethyl Isothiocyanate Upregulates Death Receptors 4 and 5 and Inhibits Proliferation in Human Cancer Stem-Like Cells. BMC Cancer, 14, 591. https://doi.org/10.1186/1471-2407-14-591
Kim, H., Kim, E.H., Eom, Y.W., et al. (2006) Sulforaphane Sensitizes Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Trail)-Resistant Hepatoma Cells to Trail-Induced Apoptosis through Reactive Oxygen Species-Mediated Up-Regulation of Dr5. Cancer Research, 66, 1740-1750. https://doi.org/10.1158/0008-5472.CAN-05-1568